Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xilio Therapeutics, Inc.XLO · Entity 7122 | CHIEF MEDICAL OFFICER | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xilio Therapeutics, Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.91 · Expires 2036-09-30 | Direct | 105,000 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 105,000 · Balance 105,000 F1: The option was granted on October 1, 2026 and will vest with respect to 25% of the shares of common stock underlying the stock option on September 28, 2027, and the remaining 75% of the shares of common stock underlying the stock option will continue to vest in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on October 1, 2026 and will vest with respect to 25% of the shares of common stock underlying the stock option on September 28, 2027, and the remaining 75% of the shares of common stock underlying the stock option will continue to vest in 36 equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:33 UTC | Xilio Therapeutics, Inc. XLO · Entity 7122 | GrantStock Option (right to buy) · Derivative | 105,000 | $0.00 Strike: $8.91 | $0.00 |
DisclosureSEC source: 0001193125-26-412466 · ownership.xml · derivative · entry 1 Houvras Yariv · CIK 0002154870 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2036-09-30 F1 · derivative.exercise_date: The option was granted on October 1, 2026 and will vest with respect to 25% of the shares of common stock underlying the stock option on September 28, 2027, and the remaining 75% of the shares of common stock underlying the stock option will continue to vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.